五、著作目錄:

* corresponding author

與人工智慧演算法有關:

- Kan, H.L., <u>Tung, C.W.</u>*, Chang, S.E., Lin, Y.C.* (2022) In Silico Prediction of Parkinsonian Motor Deficits-related Neurotoxicants based on the Adverse Outcome Pathway Concept. Archives of Toxicology. 96(12): 3305-3314.
- 2. Lin, R.H., Wang, C.C., <u>Tung, C.W.</u>* (2022) A Machine Learning Classifier for Predicting Stable MCI Patients Using Gene Biomarkers. International Journal of Environmental Research and Public Health. 19(8): 4839.
- 3. Chou, C.Y., Lin, P., Kim, J., Wang, S.S., Wang, C.C.*, <u>Tung, C.W.</u>* (2022) Ensemble learning for predicting ex vivo human placental barrier permeability. BMC Bioinformatics. 22(10): 629.
- 4. Wang, C.C., Liang, Y.C., Wang, S.S., Lin, P.*, <u>Tung, C.W.</u>* (2022) A machine learning-driven approach for prioritizing food contact chemicals of carcinogenic concern based on complementary in silico methods. Food and Chemical Toxicology. 160: 112802.
- 5. Tsou, L.K., <u>Yeh, S.H.</u>, Ueng, S.H., Chang, C.P., Song, J.S., Wu, M.H., Chang, H.S., Chen, S.R., Shih, C., Chen, C.T., Ke Y.Y.* (2020) Comparative study between deep learning and QSAR classifications for TNBC inhibitors and novel GPCR agonist discovery. Scientific Reports. 10(1):16771.

與 CTSS 相關:

- 6. Lin, H. H., Chen, S. J., Shen, M. R., Huang, Y. T., <u>Hsieh, H. P.</u>, Lin, S. Y., Lin, C. C., Chang, W. W., Chang, J. Y.* (2019) Lysosomal Cysteine Protease Cathepsin S is Involved in Cancer Cell Motility by Regulating Store-Operated Ca2+ Entry. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 1866, 118517.
- 7. Chen, J. C., Uang, B. J., Lyu, P. C., Chang, J. Y., Liu, K. J., Kuo, C. C., <u>Hsieh, H. P.</u>, Wang, H. C., Cheng, C. S., Chang, Y. H., Chang, M. D.*, Chang, W. S.*, Lin, C. C.* (2010) Design and Synthesis of alpha-Ketoamides as Cathepsin S Inhibitors with Potential Applications against Tumor Invasion and Angiogenesis. Journal of Medicinal Chemistry. 53, 4545-4549.

與新藥研發相關:

- 8. Li, M. C., Coumar, M., Lin, Y. Lin, Y. S., Huang, G. L., Chen, C. H., Lien, T. W., Wu, Y. W., Chen, Y. T., Chen, C. P., Huang, Y. C., Yeh, K. C., Yang, C. M., Kalita, B., Pan, S. L., Hsu, J.TA., Yeh, T. K., Chen, C. T., Hsieh, H. P.* (2023) Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer. Journal of Medicinal Chemistry. accepted
- 9. Kuppusamy, R., Hsu, Y.T., Ke, Y.Y., Chang, P.W., Chang, Y.C., Chang, H.F., Wang, P.C., Lin, Y.H., Huang, Y.C., Yeh, T.K., Chuang, J.Y., Loh, H.H., Shih, C., Chen, C.T., Yeh, S.H*., Ueng, S.H*. (2022) Benzo[b]thiophene-2-carboxamides as novel opioid receptor agonists with potent analgesic effect and reduced constipation. European journal of medicinal chemistry. 243, 114728.
- 10. Lee, K. H., Yen, W. C., Lin, W. H., Wang, P. C., Lai, Y. L., Su, Y. C., Chang, C. Y., Wu, C. S., Huang, Y. C., Yang, C. M., Chou, L. H., Yeh, T. K., Chen, C. T., Shih, C., <u>Hsieh, H. P.*</u> (2021) Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model. Journal of Medicinal Chemistry. 64, 14477-14497.
- 11. Li, M. C., Lin, W. H., Wang, P. C., Su, Y. C., Chen, P. Y., Fan, C. M., Chen, C. P., Huang, C. L., Chiu, C. H., Chang, L., Chen, C. T., Yeh, T. K., <u>Hsieh, H. P.*</u> (2021) Design and Synthesis of Novel Orally

- Selective and Type II Pan-TRK Inhibitors to Overcome Mutations by Property-Driven Optimization. European journal of medicinal chemistry. 224, 113673
- 12. Lin, S. Y., Hsu Yung, C., Peng, Y. H., Ke, Y. Y., Lin, W. H., Sun, H. Y., Kuo, F. M., Chen, P. Y., Lien, T. W., Chen, C. H., Chu, C. Y., Wang, S. Y., Yeh, K. C., Chen, C. P., Hsu, J. TA, Wu, S. Y., Yeh, T. K., Chen, C. T., Hsieh, H. P.* (2019) Discovery of Clinical Candidate DBPR112, a Furanopyrimidine-based Epidermal Growth Factor Receptor Inhibitor for the Treatment of Non-Small Cell Lung Cancer. Journal of Medicinal Chemistry. 62, 10108-10123.
- 13. Lin, S.Y., Kuo, Y.H., Tien, Y.W., Yi-Yu Ke, Y.Y., Chang, W.T., Chang, H.F., Ou, L.C., Law, P.Y., Xi, J.H., Tao, P.L., Loh, H.H., Chao, Y.S., Shih, C., Chen, C.T., <u>Yeh, S.H*</u>., Ueng, S.H*. (2019) The in vivo antinociceptive and μ-opioid receptor activating effects of the combination of N-phenyl-2′,4′-dimethyl-4,5′-bi-1,3-thiazol-2- amines and naloxone. European journal of medicinal chemistry. 167, 312-323.

天然物合成在藥物應用:

14. Chen, C. M., Shiao, H. Y., Uang, B. J., <u>Hsieh, H. P.</u>* (2018) Biomimetic Syntheses of (±)-Isopalhinine A, (±)-Palhinine A, and (±)-Palhinine D. Angewandte Chemie International Edition in English. 57, 15572-15576. 獲得德國蒂姆醫學出版社 SYNFACTS 主編蘇黎世聯邦理工學院 Erick M. Carreira 教授選為 "synfact of the month" 作專文介紹 (Synfacts, 2019, 15, 1)。榮獲第十五屆永信李天德醫藥科技獎之「傑出論文獎」。

與動物實驗相關:

- 15. Chen, Y.H., Wu, K.J., Hsieh, W., Harvey, B.K., Hoffer, B.J., Wang, Y., <u>Yu, S.J.*</u> (2021) Administration of AAV-alpha Synuclein NAC antibody improves locomotor behavior in rats oversspressing alpha Synuclein. Genes. 12: 948.
- 16. Chen, S.S., Chen, H., <u>Yu, S.J.</u>, Chen, Y.H., Wang, Y*. (2021) Alleviation of methamphetamine sensitization by partial lesioning dopaminergic terminals with 6-hydroxydopamine in nucleus accumbens. Cell Transplant. 30:1-8.
- 17. Huang, Y.H., Wu, Y.W., Chuang, J.Y., Chang, Y.C., Chang, H.F., Tao, P.L., Loh, H.H., <u>Yeh, S.H</u>*. (2020) Morphine produces potent antinociception, sedation, and hypothermia in humanized mice expressing human mu opioid receptor splice variants. PAIN. 161(6):1177-1190.
- 18. Chao, P.K., Chang, H.F., Chang, W.T., Yeh, T.K., Ou, L.C., Chuang, J.Y., Hsu, T.A., Tao, P.L., Loh, H.H., Shih, C., Ueng, S.H*., Yeh, S.H*. (2020) BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine. Neuropharmacology. 166:107678.
- 19. Yu, S.J., Chen, S.C., Yang, Y.Y., Glotfelty, E.J., Jung, J., Kim,H.K., Choi, H.I., Choi, D.S., Hoffer, B.J., Greig, N.H., Wang, Y*. (2020) PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson's Disease. Frontiers in Neuroscience. 14:785.
- 20. <u>Yu, S.J.</u>, Wang, Y.C., Chang, C.Y., Hsieh, W., Chen, S., Yang, C.S., Lin, S.Z., Wang Y* (2019) NanoCsA improves the survival of human iPSC transplant in hemiparkinsoniam rats. Brain Research. 1719:124-132.
- 21. Chen, S., <u>Yu, S.J.</u>, Li, Y., Lecca, D., Glotfelty, E., Choi, H.I., Hoffer, B.J., Greig, N.H., Kim, D.S., Wang, Y*. (2018) Post-treatment with PT302, a Long-acting Exendin-4 Sustained Release Formulation, Reduces Neurodegeneration of Dopaminergic Neurons in a 6-Hydroxydopamine Rat Model of Parkinson's Disease. Scientific Reports. 8: 10722.